3 Key Takeaways
Plain English Summary- 01Core Finding
Delivered via microvascular inflammation in kidney transplants: finally an effective treatment?, this clinical practice approach targets Inflammation · Antibodies.
- 02Study Evidence
Study design used a clinical evidence review protocol to track clinical outcomes.
- 03Practical Meaning
Benefits and risks vary by individual health history — discuss with a healthcare professional.
What This Means for You
As demonstrated in a study in this issue of Kidney International, targeting CD38, a glycoprotein expressed on both plasma cells and natural killer cells, shows great promise in treating microvascular inflammation in kidney transplants.
The Discovery
Microvascular inflammation-glomerulitis and peritubular capillaritis-is the hallmark histologic lesion of antibody-mediated allograft rejection and may also occur in the absence of donor-specific antibodies. In either case, microvascular inflammation leads to graft loss, and it has proven difficult to treat.
How It Works, Simply
This nephrology research focuses on inflammation · Antibodies. Researchers evaluated it using a standard-of-care clinical practice · Clinical evidence review at the clinical practice stage of medical research.
3 Key Takeaways
Clinical Takeaways- 01Core Finding
Delivered via microvascular inflammation in kidney transplants: finally an effective treatment?, this clinical practice approach targets Inflammation · Antibodies.
- 02Study Evidence
Study design used a clinical evidence review protocol to track clinical outcomes.
- 03Practical Meaning
Benefits and risks vary by individual health history — discuss with a healthcare professional.
Biological Mechanism & Study Design
Study Design & Cohort
Clinical evidence review
Standard-of-care clinical practice · Clinical evidence review · Clinical Practice
Biological Pathway & Modality
Inflammation · Antibodies
Intervention: Microvascular inflammation in kidney transplants: finally an effective treatment?
Experimental Findings & Endpoints
Microvascular inflammation-glomerulitis and peritubular capillaritis-is the hallmark histologic lesion of antibody-mediated allograft rejection and may also occur in the absence of donor-specific antibodies.
In either case, microvascular inflammation leads to graft loss, and it has proven difficult to treat.
Clinical Translation & Practice Context
As demonstrated in a study in this issue of Kidney International, targeting CD38, a glycoprotein expressed on both plasma cells and natural killer cells, shows great promise in treating microvascular inflammation in kidney transplants.
The Bottom Line · Clinical Pearl
“As demonstrated in a study in this issue of Kidney International, targeting CD38, a glycoprotein expressed on both plasma cells and natural killer cells, shows great promise in treating microvascular inflammation in kidney transplants.”
Published in Kidney International · Current Stage: Clinical Practice